NASDAQ$LXRX
Lexicon Pharmaceuticals Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
LXRX Q2 2024 — $1.6M revenue, 0.17 EPS
Risk Factors” and in our annual report on Form 10-K for the year ended December 31, 2023, that may cause our or our industry’s actual results, levels of activity, performance or achievements to be mat. Lexicon Pharmaceuticals Inc reported Q2 2024 results. Diluted EPS came in at $0.17. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.
- Revenue: $1.6M.
- Diluted EPS: $0.17.
- Filed on Form 10-Q (accession 0001062822-24-000046).
Headline financials
Revenue & EPS history
Lexicon Pharmaceuticals · Revenue · Quarterly
$1.65M
Revenue by segment
Lexicon Pharmaceuticals · $162K total across 2 segments · Q3 2023
- Net Product Revenue$148K—91.4%
- Royalties and Other$14K—8.6%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
+0.4%
Avg return
Earnings day
+2.8%
Avg return
5 days after
-0.4%
Avg return
30 days after
56%
36 / 64 earnings
Positive
+30.6%
Q3 2015
Best reaction
-26.0%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.4% | +50.0% | +19.4% | |
| Q4 2025 | -0.6% | +1.8% | -2.5% | |
| Q3 2025 | +3.0% | +13.0% | +1.4% | |
| Q1 2025 | +3.1% | +22.2% | +24.1% | |
| Q4 2024 | +6.6% | +2.7% | +13.5% | |
| Q3 2024 | -14.2% | -22.8% | -35.4% | |
| Q2 2024 | -24.4% | -27.1% | -23.1% | |
| Q1 2024 | +5.5% | +7.3% | +3.0% | |
| Q4 2023 | +16.1% | +19.8% | -6.9% | |
| Q3 2023 | -17.2% | -14.4% | +0.0% | |
| Q2 2023 | -1.1% | -3.7% | -10.6% | |
| Q1 2023 | +12.3% | +43.0% | +11.1% | |
| Q4 2022 | +21.8% | +17.3% | +10.5% | |
| Q3 2022 | +8.7% | +13.1% | -1.0% | |
| Q2 2022 | +13.5% | +19.4% | +16.5% | |
| Q1 2022 | -7.2% | -9.8% | -6.7% | |
| Q4 2021 | -26.0% | -25.3% | -26.3% | |
| Q3 2021 | -11.2% | -9.8% | -25.5% | |
| Q2 2021 | +2.0% | -4.7% | +28.8% | |
| Q1 2021 | -0.4% | -3.7% | -3.5% | |
| Q4 2020 | -1.4% | -2.6% | -23.8% | |
| Q3 2020 | -9.0% | -9.8% | +32.8% | |
| Q2 2020 | +11.5% | +12.6% | +0.0% | |
| Q1 2020 | +3.4% | -7.3% | -1.0% | |
| Q4 2019 | -10.6% | +3.5% | -17.2% | |
| Q3 2019 | -8.6% | -8.8% | +26.5% | |
| Q2 2019 | -21.1% | -19.9% | -20.5% | |
| Q1 2019 | +4.7% | +20.9% | -7.2% | |
| Q4 2018 | +2.2% | +6.3% | -15.3% | |
| Q3 2018 | +8.4% | +8.8% | +3.4% | |
| Q2 2018 | -3.0% | -11.8% | -6.2% | |
| Q1 2018 | +8.4% | +17.3% | +52.2% | |
| Q4 2017 | +1.3% | +4.5% | -1.3% | |
| Q3 2017 | -6.3% | +0.8% | +8.4% | |
| Q2 2017 | -4.4% | -3.7% | -7.1% | |
| Q1 2017 | +2.4% | +2.2% | -9.5% | |
| Q4 2016 | +9.0% | +11.0% | -4.8% | |
| Q3 2016 | -4.2% | -3.0% | -1.3% | |
| Q2 2016 | +1.6% | +0.6% | -11.8% | |
| Q1 2016 | -15.6% | — | — | |
| Q4 2015 | +24.4% | — | — | |
| Q3 2015 | +30.6% | — | — | |
| Q2 2015 | -8.6% | — | — | |
| Q1 2015 | -5.7% | — | — | |
| Q4 2014 | +14.3% | — | — | |
| Q3 2014 | +2.1% | — | — | |
| Q2 2014 | -6.6% | — | — | |
| Q1 2014 | +1.4% | — | — | |
| Q4 2013 | +3.8% | — | — | |
| Q3 2013 | -2.6% | — | — | |
| Q2 2013 | +7.8% | — | — | |
| Q1 2013 | +2.5% | — | — | |
| Q4 2012 | +1.9% | — | — | |
| Q3 2012 | -9.6% | — | — | |
| Q2 2012 | +3.7% | — | — | |
| Q1 2012 | +1.3% | — | — | |
| Q4 2011 | +5.6% | — | — | |
| Q3 2011 | -9.9% | — | — | |
| Q2 2011 | -7.1% | — | — | |
| Q1 2011 | +1.9% | — | — | |
| Q4 2010 | +6.3% | — | — | |
| Q3 2010 | -3.7% | — | — | |
| Q2 2010 | -0.7% | — | — | |
| Q1 2010 | +8.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro